Comparing 4 approaches for HIV infections
Official title: The MARVIN Chatbots to Provide Information for Different Health Conditions
A Master Research Protocol to Adapt and Evaluate an Artificial Intelligence Based Conversational Agent to Provide Information for Different Health Conditions: the MARVIN Chatbots
- 4 groups
- 2 sites in Montreal
- Recruiting
Interventions (4)
- Other intervention
MARVIN
Chatbot on Meta (Facebook) Messenger for HIV Patients
- Other intervention
MARVIN-Pharma
Chatbot on Meta (Facebook) Messenger for community pharmacists
- Other intervention
MARVINA
Chatbot on Meta (Facebook) Messenger for breast cancer patients
- Other intervention
MARVIN-CHAMP
CHatbot to Assist the Management of Pediatric patients with infectious conditions (CHAMP)
Canadian Sites (2)
2 of 2 recruiting
- Recruiting
Centre hospitalier de l'Université de Montréal (CHUM)
Montreal, Quebec
- Recruiting
McGill University Health Centre (MUHC)
Montreal, Quebec
Eligibility Criteria
See who this study is looking for12 criteria
The trial’s own eligibility text, word for word from the registry. Only the trial site can say who takes part.
Inclusion
- +for all objectives:
- +being 14 years or older;
- +being fluent in English and/or French;
- +being able to understand the requirements of study participation and provide informed consentInformed consentThe process of being told what taking part involves, then choosing freely.Read more → during the duration of the study;
- +having access to a smartphone, tablet, or computer at home/at workplace;
- +having access to an internet connection at home or data plan on their device.
- +Inclusion CriteriaInclusion criteriaThe things you must have or be for a study to consider you.Read more → Specific to objectives 2 and 3:
- +accept to use a Facebook Messenger-based Chatbot;
- +accept to use or create a personal Facebook account;
- +accept Facebook's privacy and data security policies.
Exclusion
- −not meeting the inclusion criteriaInclusion criteriaThe things you must have or be for a study to consider you.Read more →
- −any reason, in the opinion of the investigatorPrincipal investigatorThe doctor or researcher responsible for running the study at a site.Read more →, which would make the candidate inappropriate for participation in an investigative study involving a chatbot (e.g., cognitive deficit)
In plain language
Assembled directly from this trial’s registry record. Every sentence traces to a field below — nothing here is generated or interpreted.
What this study is
This study does not fall into the standard research categories.
This study is not organised into the usual phase numbers — that is common for device, behavioural, and diagnostic research.
From the trial registry
Built from these fields:
- designModule.designInfo.primaryPurpose
- designModule.phases
Who receives what
There are 4 groups in this study.
Group A receives MARVIN.
Registry label: A: MARVIN: a Chatbot for HIV patients
Group B receives MARVIN-Pharma.
Registry label: B: MARVIN: a Chatbot for Community Pharmacists
Group C receives MARVINA.
Registry label: C: MARVINA: a Chatbot for Breast Cancer Patients
Group D receives MARVIN-CHAMP.
Registry label: D: MARVIN CHAMP: a Chatbot for Pediatric Infectious Conditions
From the trial registry
Built from these fields:
- armsInterventionsModule.armGroups[].label
- armsInterventionsModule.armGroups[].type
- armsInterventionsModule.armGroups[].interventionNames
How the study is run
Groups are assigned by the study team using set rules, rather than by chance.
This study is open-labelOpen-labelEveryone knows which treatment is being given — nothing is hidden.Read more →: everyone knows which treatment is being given, including you and the study team.
From the trial registry
Built from these fields:
- designModule.designInfo.allocation
- designModule.designInfo.maskingInfo.masking
Is there a placebo?
This study does not list a placeboPlaceboA dummy treatment with no active medicine, used for comparison.Read more → group.
From the trial registry
Built from these fields:
- armsInterventionsModule.armGroups[].type
- armsInterventionsModule.armGroups[].interventionNames
Who the study is looking for
The study lists a minimum age of 14 years, with no upper limit given.
The study is open to people of any sex.
The study accepts healthy volunteersHealthy volunteerSomeone without the condition being studied who takes part anyway.Read more → as well as people with the condition.
These are the criteria the study lists. Only the trial siteTrial siteA hospital or clinic where a study is actually run.Read more → can decide whether someone can take part.
From the trial registry
Built from these fields:
- eligibilityModule.minimumAge
- eligibilityModule.sex
- eligibilityModule.healthyVolunteers
How big and how long
The study aims to enrol about 400 people.
The study is currently expected to finish around December 2034.
The main measurement is taken over: Immediately, after 1-month of testing - objective 2.
From the trial registry
Built from these fields:
- designModule.enrollmentInfo.count
- statusModule.completionDateStruct.date
- outcomesModule.primaryOutcomes[].timeFrame
What the study measures
Usability Metric for User eXperience (UMUX-Lite) — measured over Immediately, after 1-month of testing - objective 2.
Acceptability E-Scale (AES) — measured over Immediately after 1-month of testing - objective 2.
Change in Acceptability E-Scale (AES) over 12 months — measured over Once every 3 months within 12 months.
Change in Intervention Appropriateness Measure (IAM) over 12 months — measured over Once every 3 months within 12 months.
The study lists 1 further main measurements.
From the trial registry
Built from these fields:
- outcomesModule.primaryOutcomes[].measure
- outcomesModule.primaryOutcomes[].timeFrame
Source: NCT05789901 on ClinicalTrials.gov. The full registry text is further down this page — this summary never replaces it.
Not medical advice. What do these terms mean?
What is being tested — in plain terms
About MARVINOther
Chatbot on Meta (Facebook) Messenger for HIV Patients
From the trial registry — its own words, unedited.
What a other is here: An intervention the registry did not place in another category.
Read the full explanation → · in clinical review
About MARVIN-PharmaOther
Chatbot on Meta (Facebook) Messenger for community pharmacists
From the trial registry — its own words, unedited.
What a other is here: An intervention the registry did not place in another category.
Read the full explanation → · in clinical review
About MARVINAOther
Chatbot on Meta (Facebook) Messenger for breast cancer patients
From the trial registry — its own words, unedited.
What a other is here: An intervention the registry did not place in another category.
Read the full explanation → · in clinical review
About MARVIN-CHAMPOther
CHatbot to Assist the Management of Pediatric patients with infectious conditions (CHAMP)
From the trial registry — its own words, unedited.
What a other is here: An intervention the registry did not place in another category.
Read the full explanation → · in clinical review
Common questions
Answered from this trial’s registry record. Where the record doesn’t say, these answers say so rather than filling the gap.
Am I eligible for this trial?
Only the trial siteTrial siteA hospital or clinic where a study is actually run.Read more → can decide whether someone can take part. Concord cannot make that determination, and neither can any tool that has not examined you.
What the study lists: a minimum age of 14 years.
The full inclusionInclusion criteriaThe things you must have or be for a study to consider you.Read more → and exclusion criteriaExclusion criteriaThe things that would prevent someone from taking part.Read more → are published on this page, exactly as the study team wrote them.
The useful next step is to bring this trial to your doctor. Answering a few questions first gives them something concrete to review.
From the trial registry
- eligibilityModule.minimumAge
- eligibilityModule.eligibilityCriteria
Is there a placebo?
This study does not list a placeboPlaceboA dummy treatment with no active medicine, used for comparison.Read more → group.
From the trial registry
- armsInterventionsModule.armGroups[].type
Would I know which treatment I am getting?
This study is open-labelOpen-labelEveryone knows which treatment is being given — nothing is hidden.Read more →: everyone knows which treatment is being given, including you and the study team.
Groups are assigned by the study team using set rules, rather than by chance.
From the trial registry
- designModule.designInfo.maskingInfo.masking
- designModule.designInfo.allocation
Who can join?
The study lists a minimum age of 14 years, with no upper limit given.
It is open to people of any sex.
It accepts healthy volunteersHealthy volunteerSomeone without the condition being studied who takes part anyway.Read more → as well as people with the condition.
Only the trial siteTrial siteA hospital or clinic where a study is actually run.Read more → can confirm whether a particular person can take part.
From the trial registry
- eligibilityModule.minimumAge
- eligibilityModule.sex
- eligibilityModule.healthyVolunteers
How long would this take?
The study's main measurement is taken over: Immediately, after 1-month of testing - objective 2.
The study as a whole is currently expected to finish around 2034-12-31.
How long any one person takes part can differ from the study length. The study team can tell you what the schedule looks like in practice.
From the trial registry
- outcomesModule.primaryOutcomes[].timeFrame
- statusModule.completionDateStruct.date
How many people are taking part?
The study aims to enrol about 400 people.
From the trial registry
- designModule.enrollmentInfo.count
Where is this happening?
This study lists one location: Montreal, Quebec, Canada.
Sites can open and close during a study, so confirm with the team before travelling.
From the trial registry
- trial_locations
About This Trial
This research is a continuation of a usability study with the MARVIN chatbot. The investigators aim to adapt the MARVIN chatbot to open it to other health domains (e.g. breast cancer) and populations (e.g. pharmacists). Therefore, this protocol constitutes a master research protocol that will englobe different research projects with individual chatbots. The investigators adopt an adaptive platform trial design, which will allow flexibility in handling multiple interventions adapted to different populations while retaining the characteristics of a platform trial design allowing early withdrawal of ineffective trial arms based on interim data (implementation outcomes) and introduction of new trial arms.
Think this trial might be right for you?
Complete a quick intake form and we will match you with this and other relevant trials based on your medical profile.
See if this trial could fit youThis page is for informational purposes only and does not constitute medical advice. Clinical trial eligibility can only be determined by the trial site after proper screening. Trial information is sourced from ClinicalTrials.gov and may not reflect the most current status. Always consult your healthcare provider before making decisions about clinical trial participation.